Identifying new chemotherapeutic agents and characterizing mechanisms of resistance may improve cancer treatment. The Anticancer Drug Screen of the National Cancer Institute uses 60 cell lines to identify new agents. Expression of mdr-1/P-glycoprotein was measured by quantitative PCR. Expression was detected in 39 cell lines; the highest levels were in renal and colon carcinomas. Expression was also detected in all melanomas and central nervous system tumors, but in only one ovarian carcinoma and one leukemia cell line. Using a modified version of the COMPARE program, a high correlation was found between expression of mdr-1 and cellular resistance to a large number of compounds. Evidence that these compounds are P-glycoprotein substrates includes: (a) enhancement of cytotoxicity by verapamil; (b) demonstration of cross-resistance in a multidrug-resistant cell line, (c) ability to antagonize P-glycoprotein, increasing vinblastine accumulation by decreasing efflux; and (d) inhibition of photoaffinity labeling by azidopine. Identification of many heretofore unrecognized compounds as substrates indicates that P-glycoprotein has a broader substrate specificity than previously recognized. This study confirms the validity of this novel approach and provides the basis for similar studies examining a diverse group of gene products, including other resistance mechanisms, putative drug targets, and genes involved in the cell cycle and apoptosis. (J. Clin. Invest. 1995. 95:2205-2214 
Introduction
The success of chemotherapy in a large number of malignancies has stimulated efforts to identify new agents and improve existing therapies. The identification of new agents is being pursued with both an expanded screening in established models and rational drug design ( 1, 2). The National Cancer Institute's (NCI) Anticancer Drug Screen seeks to identify new agents with potential antitumor activity using a panel of 60 cell lines from a broad range of malignancies. Natural products as well as semisynthetic and synthetic compounds are screened, and a sensitivity pattern is determined. Using this information and a computer-based pattern identification program designated COMPARE, potential targets of unknown compounds have been predicted (3, 4) .
The recognition of drug resistance as a major reason for the failure of chemotherapy has stimulated efforts to identify mechanisms of drug tolerance. Success in this search offers the possibility that therapies may be designed to overcome mechanisms of resistance. This approach has been pursued aggressively in vitro with models of multidrug resistance. Recognition of the role of P-glycoprotein as a drug efflux pump by BechHanson et al. (5) and Juliano and Ling (6) and by the subsequent work by Tsuruo and co-workers (7) (8) (9) demonstrating reversal of drug tolerance by verapamil has stimulated efforts to antagonize the function of this membrane phosphoglycoprotein. Expression of P-glycoprotein has been documented in a variety of human cancers, and in some malignancies it has been shown to be a negative prognostic factor (10) (11) (12) (13) (14) . Although precise quantitation has not been obtained, the sensitivity of the methods and the standard cell lines used for comparison suggest that a range of levels can be found. Several studies to date have documented increases in P-glycoprotein expression after treatment with natural products, supporting a role for this protein in clinical drug resistance (15) (16) (17) .
With the ultimate goal of using the Anticancer Drug Screen to identify and characterize P-glycoprotein antagonists and to compare the efficacy of these antagonists alone or in combination in a large number of malignancies, we sought initially to determine the expression of P-glycoprotein in the cell lines comprising the Anticancer Drug Screen. This offered the possibility to evaluate a quantitative PCR methodology previously described (18) . Although an earlier study had documented expression in a large number of the cell lines in the Drug Screen, the occurrence of early plateau in the PCR-based methodology used in that analysis underestimated the level of expression in a number of the cell lines ( 19) . In the present study we describe a quantitative PCR determination of mdr-I/P-glycoprotein expression and describe the correlations derived from these measurements. The reliability and accuracy of the quantitative PCR methodology are validated. The identification of a large number of putative P-glycoprotein substrates is presented. The potential use of the Drug Screen to characterize and understand mechanisms of resistance is discussed. Cell lines. The cell lines comprising the National Cancer Institute's Anticancer Drug Screen Panel were obtained and processed as previously described (2). Briefly, after an initial acquisition, in vitro expansion was followed by cryopreservation of a large number of master stock samples, for serial rethawing at 20-passage intervals.
In vitro assay method. Anticancer drug screening was accomplished as previously described using a sulforhodamine-B assay to determine growth inhibition/cell kill (2). Nine cell lines with a broad range of mdr-1 expression were selected to evaluate the effect of verapamil on a series of potential mdr-substrates. Cells were inoculated onto 96-well tissue culture plates at densities ranging from 5,000 to 20,000 cells/ well. The culture plates were incubated at 370C in 5% CO2 for 24 h, then verapamil was added at 5 (20) . Vinblastine accumulations were carried out for 1 h; efflux studies were performed for 10 mmn after a 2-h loading period.
In vitro cytotoxicity assay. Cytotoxicity assays with parental SW620 cells and multidrug-resistant SW620 Ad 300 cells were done in 96-well microtiter plates using the colorimetric methods described by Skehan et al. (21) . Cells were seeded at a density of 1,000/well in 100 asl of growth medium. Cytotoxic agents diluted in 100 aul of the growth medium were added 24 h after seeding, and the cells were incubated for 96 h. Cells were fixed with TCA, stained with 0.4% (wt/vol) sulforhodamine-B dissolved in 1% acetic acid, and rinsed with 1% acetic acid to remove unbound dye. Bound dye was solubilized and the OD at 564 nm was measured.
Photoaffinity labeling with 3H-Azidopine. 4 X 106 cells were photolabeled in 100 ILI of PBS with 4 ,uCi of 'H-azidopine, as previously described (22) .
COMPARE analysis and determination of Pearson and Spearman correlation coefficients. The version of COMPARE used in this work differs from the original version of COMPARE that made comparisons based on a calculated mean difference in "deltas" (3) . The current version of COMPARE is configured to calculate pairwise correlations with the -log10 (minus log10) of one of the specific NCI cell line activity parameters: GI5O, TGI, or LC50 (23) . For instance, the GI5O is the NCI designation for a time 0-corrected ICm, the concentration of agent causing a 50% growth inhibition. Thus, -log10 (G150)s for a "seed" or probe compound are correlated with the corresponding data from each compound in a database. In this paper, the G15O data were used in the COMPARE studies, and the seed data were derived from a different source as described below. The correlation coefficients used are generally the Pearson correlation coefficients output by the SASS procedure PROC CORR (SAS Institute Inc., Cary, NC) using the out=outp option. We also calculated Spear-man correlation coefficients using the out=outs option for PROC CORR for these correlations employing a small subset of the available seed values. The Spearman correlations were investigated because of a concern that, for these small subsets, the seed data deviated too much from a normal distribution to use the Pearson method. In fact, the Spearman correlation coefficients differed little from the Pearson correlation coefficients.
This application of COMPARE differs from all previously reported applications in that the seed data are not generated from actual screening data. Instead, the seed data represent measurements of a multidrug resistance-related property of the cell lines used in the NCI screen. The larger the values of this multidrug resistance-related property for a particular cell line, the greater the potential drug resistance of that cell line to those agents subject to the particular multidrug resistance property (by being a good substrate for P-glycoprotein, for instance). The COMPARE databases store the screening data as -log(G150) for historical reasons related to the mean graph sign conventions. This means that data from more drug-resistant cell lines are stored with smaller values than those from drug-sensitive cell lines. Therefore, by taking the negative of the multidrug resistance property measurements (the negative of the mdr-1 values), the highest positive correlation coefficients should be obtained with database compounds whose drug resistance was best correlated with the multidrug resistance property. Finally, to make the operation of this special application of COMPARE more easily visualized, we invoked the paradigm of the mean graph (3) and constructed a mean graph of the multidrug resistance property's seed values.
Results
Previous experience measuring mdr-1 expression in both cell lines and tissue samples suggested that, in a large fraction of the cell lines in the Anticancer Drug Screen, expression would be detectable only with use of the polymerase chain reaction. Figs. 1 and 2 present representative results for renal cell and colon carcinoma cell lines. Varying amounts of RNA were analyzed in serial twofold dilutions, ensuring that amplification was in the exponential range. A twofold increase indicated that the amplification proceeded in the exponential range and that an accurate value could be obtained. Similar measurements were carried out using mdr-1 and ,3-2 microglobulin primers in separate reactions. The level of mdr-1 in all cell lines was determined at least twice in two independent serial dilutions and in some cases four times. These results are summarized in Fig. 3 . The values used in this figure were obtained by using carefully measured RNA concentrations to standardize for input RNA. Similar results were obtained when mdr-1 values were calculated using /3-2 microglobulin as the internal standard. This is graphically depicted in Fig. 4 , which demonstrates the results when all cell lines are plotted individually. In this graph the xcoordinates are the mdr-1 values determined using the measured RNA concentration for standardization; the y-coordinates are the mdr-1 values calculated using /-2 microglobulin expression as an internal control. The line presents the ideal results that would be obtained if both mdr-1 values were identical. The distribution around this ideal presents graphically the similar results obtained with both standardizations, validating the use of either mdr-1 value for further studies.
It has been previously established that the sensitivity profile or fingerprint of a given drug can predict its mechanism of action using the COMPARE program (4 compounds. Although this analysis identified a large number of compounds that were not natural products, examination of the results suggested that potential P-glycoprotein substrates had been identified. Specifically, this analysis identified a large number of the compounds selected in the previous analysis. The 100 compounds with Pearson correlation coefficients > 0.867 included 14/19 from Table I and 8/9 for which cytotoxicity had been modulated by verapamil. 14 compounds in Table HI for which sufficient quantities were available were evaluated further. Using four different approaches, all 14 were determined to be P-glycoprotein substrates. These four methods of analysis were chosen because they measure different properties of potential P-glycoprotein substrates and complement each other. The results are depicted in Figs. 8 and 9 . First, the various compounds were tested for their effect on the accumulation and efflux of vinblastine in a multidrug-resistant cell line. For these studies, an Adriamycinselected subline, SW620 Ad 300, derived from SW620 cells by continuous exposure to Adriamycin and expressing high levels of P-glycoprotein, was used. Previous characterization has demonstrated a predominant role for P-glycoprotein in the resistance of this subline (24) . Vinblastine accumulation in the Adriamycin-selected SW620 Ad 300 cell line is -5% that in parental SW620 cells. The results of this analysis are depicted in A and B of Fig. 8 . Two known P-glycoprotein "substrates" (vincristine and paclitaxel) and the antagonist verapamil are included for comparison. The concentration of all compounds was 10 ,Sm. Under these conditions, 12 of the 14 compounds were able to increase vinblastine accumulation above that in the SW620 Ad 300 cells. (For NSC 626852, background interference precluded a precise result from being obtained.) The 12 compounds tested inhibited vinblastine efflux. C shows the results obtained when cross-resistance was determined using parental SW620 cells and the multidrug-resistant subline SW620 Ad 300. Cross resistance was demonstrated for 10 of the 14 compounds; no cross-resistance was observed with 2 others (NSC 626852 and 643179); and a determination was not possible with 2 others (NSC 618094 and 649087), both of which were not toxic to either the parental or the resistant cells up to a concentration of 10 MM. The apparent discrepancies between the different measurements support the use of different approaches to determine whether a compound is recognized by P-glycoprotein, as discussed below.
In addition to these three approaches, the effect of the 14 compounds on 3H-azidopine labeling was compared to that of vinblastine. Competition with 50 gm vinblastine or one of the 14 compounds was performed in live SW620 Ad 300 cells as shown in Fig. 9 . Of the 14 compounds, 6 were as or more effective than vinblastine, while 8 others were able to decrease labeling to a lesser extent.
Discussion
The present study describes the quantitation of mdr-1 expression by PCR in the 60 cell lines of the National Cancer Institute's Anticancer Drug Screen Program. Expression of mdr-l /P-glycoprotein was detected in 39/60 cell lines. Renal cell carcinomas and colon carcinomas had the highest levels of expression, while the majority of ovarian carcinomas and leukemia/ lymphomas were negative. Correlation of mdr-1 expression with sensitivity identified a large number of compounds that were demonstrated to be P-glycoprotein substrates by one or more of several approaches. These results validated the reliability of the quantitative PCR methodology used. The structural diversity of these compounds indicates that P-glycoprotein can recognize a spectrum of structures greater than that previously recognized. The (0) 32944 (74) 648114 (0) 346243 (8) 626316 (30) 642179 (29) 526417 (57) 344003 (10) Ib
Control (1 00 validate a quantitative PCR methodology previously described, with the ultimate goal of using this resource to characterize newly developed P-glycoprotein antagonists. To that end, we began by characterizing expression in the 60 cell lines using a precise method for quantitation by PCR as previously described ( 18) . This quantitative approach, although labor intensive, does not depend on the addition of exogenous templates but relies on the kinetics of the amplification reaction and the knowledge that any measurement in the exponential range provides an accurate measurement of the amount of message. Its original description is extended in the present study and its utility and reliability are confirmed by the correlations established with drug resistance, which were in turn confirmed by one or more independent experiments. The control SW620 cell line has been previously determined to have 2.3 mdr-l molecules/ng of total RNA. Assuming that the amount of RNA harvested per cell is similar for all the cell lines, then expression in the 60 cell lines ranges from 0 to > 1,700 mdr-1 molecules/ng of total RNA. The results in the present study differ from those obtained in a previous study, because the methodology used in that analysis resulted in early plateau and underestimated the level of mdr-1 (19) . Thus, although similar results were obtained for cell lines with low levels of mdr-I and those without mdr-l, much lower values were obtained in the previous analysis for the cell lines with higher mdr-l levels. It is these higher values that are more valuable in an analysis such as the present one.
Several lines of evidence support the results obtained with the quantitative PCR methodology used to measure mdr-l levels. The range and frequency of mdr-l expression in the present study are consistent with previous reports and our unpublished experience indicating a high frequency and level of expression in renal cell and colon carcinomas, and lower levels in other malignancies (13, (25) (26) (27) (28) (29) (30) (31) (62) 649087 (15) 640085 (41) 626852 (28) carcinoma cell lines. In addition, a high correlation has been found between the mdr-1 levels and those of a functional assay, rhodamine accumulation, in the same cell lines (our unpublished observations). Finally, the compounds identified as putative P-glycoprotein substrates were confirmed by one of several assays to be recognized by P-glycoprotein.
Previous analyses have used the COMPARE program and drug sensitivity values to identify patterns common to drugs that share a common target or mechanism of action (4). These fingerprints have also been used to identify putative targets of new or unknown compounds. The high correlations observed in these analyses have suggested that the target and mechanism of action are important determinants of drug sensitivity as determined in the Drug Screen assays. Thus, it was interesting to find that seeding the analysis with values of a mechanism of resistance (mdr-1) resulted in a high correlation for many compounds. The validity of these correlations was confirmed by experiments that indicated that these compounds were P-glycoprotein substrates. This result indicates that mechanism(s) of resistance can also influence the drug sensitivity profile. They indicate that similar analyses with other putative mechanisms of resistance may be very valuable.
Although the correlation coefficients for the drugs commonly identified as P-glycoprotein substrates (Adriamycin, vincristine, vinblastine, etoposide, and actinomycin-D) were not as high as those of other compounds, they were higher than commonly used drugs that are known not to be transported by P-glycoprotein, including platinum analogues, alkylating agents, and antimetabolites. In addition, it was interesting that among anthracyclines, the correlation was higher for Adriamycin and daunomycin than for analogues that are not part of the multidrug-resistant phenotype, morpholino and cyanomorpholino Adriamycin. Since multiple putative mechanisms of resistance have been proposed for Adriamycin, one could predict that a correlation with a single mechanism of resistance would be low. With regard to the vinca alkaloids, the 2-d assay used in the Drug Screen blunts the curves, and this may have affected the correlation coefficients.
The majority of the compounds identified were heretofore not regarded as P-glycoprotein substrates. For some, one might have made such a prediction, but for others, their identification broadens the spectrum of potential P-glycoprotein substrates. Although many of these drugs do not conform to the ideal pharmacophore described by Zamora et al. (32) , the results should not be interpreted as contradictory. A compound without a specific target or with a nonmutatable target, for which Pglycoprotein is the sole mechanism of resistance, could have a higher correlation coefficient than another compound that is a better substrate. Similar comments could be made relating to the work of Ford et al. (33) .
In summary, in the present study we have demonstrated the value of a previously described method for quantitating mRNA using PCR. In the 60 cell lines of the Drug Screen, expression of mdr-1 was found in 39. A correlation was demonstrated between mdr-I expression and resistance for a large number of compounds, including many previously unrecognized P-glycoprotein substrates, validating the quantitative PCR methodology used. We conclude that P-glycoprotein has a broad specificity for transport and that its expression in a majority of human cancer cells can influence the identification of new agents. This type of analysis offers the possibility of learning more about other mechanisms of resistance and how genes can affect drug sensitivity and could help identify drugs potentially active against a target. A similar approach is currently being applied in studies with other gene products.
